You are here: Home » 2021 » Archives for November 2021

General Fusion closing oversubscribed $130 million transitional financing round

VANCOUVER, British Columbia, Nov. 30, 2021 (GLOBE NEWSWIRE) — General Fusion announced today it is closing an oversubscribed $130 million (USD) Series E funding round filled by a new syndicate of global investors. This financing, led by Temasek, significantly expands the company's portfolio of institutional, sovereign, family office, and high net worth investors, providing the prelude to a large financing round being prepared for 2022. Combined with broad financial support from the Canadian, U.K., and U.S. governments, the General Fusion Series E round supports aggressive pursuit of several near–term initiatives and milestones in its program to commercialize Magnetized Target Fusion (MTF).

In addition to a portfolio of important individual investors, which includes Jeff Bezos, Tobias Ltke, and Kam Ghaffarian, Series E brings a new syndicate of major institutional and family office investors to General Fusion. These anchoring investors include Temasek, GIC, the Jameel Investment Management Company (JIMCO), and the Business Development Bank of Canada (BDC), as well as broader participation from other capital market segments represented by investors such as a large U.S. state pension plan and the hedge fund firm Segra Capital.

“Segra Capital believes General Fusion is best positioned among its peer group to deliver fusion at a commercial scale in the near term,” said Adam Rodman, Founder and CIO, Segra Capital. “While Segra Capital has traditionally invested primarily in public markets, this compelling opportunity resonated with our core ESG and cleantech–focused partners, so we are excited to participate in this Series E financing and look forward to supporting the company in the future.”

“General Fusion's drive to shape the market for clean fusion energy is just one of the many reasons why JIMCO is investing in its commercialization program,” said Fady Jameel, a member of the Jameel Family's Investment Supervisory Board. “The global energy sector is undergoing tremendous change to secure a cleaner future for all, which JIMCO is passionate about and ready to support through investments like the one in General Fusion."

"With our 75–year history of investing in companies positively shaping the future of the core industries, we believe General Fusion's global, technologically–advanced solution to commercial fusion energy make them a leader in this growing industry."

"Collectively, the expansion of General Fusion's investor base in this Series E financing provides a strong foundation for a larger financing next year," said Greg Twinney, CFO, General Fusion. "From our technology's inception, we have had a laser focus on cultivating customers and creating a practical, clean energy solution that meets their needs. This approach resonates with investors looking to make an impact in the global energy transition."

With substantial capital support from both private and government sources, General Fusion has aggressively pursued deployment of its power–plant scale Fusion Demonstration Plant located at the UK Atomic Energy Authority's (UKAEA) Culham Centre for Fusion Energy near London. The company has also accelerated MTF technology development activities associated with its new Vancouver headquarters and opened a new facility adjacent to Oak Ridge National Laboratory in the U.S. Furthermore, General Fusion has created a Market Development Advisory Committee (MDAC) focused exclusively on fusion. The company's MDAC is currently comprised of nine leading energy companies and clean energy users representing critical markets for fusion's carbon–free, on–demand power.

"General Fusion's unique global presence, with facilities in three countries, allows us to be much more ambitious in pushing toward commercialization," said Christofer Mowry, CEO, General Fusion. "Our broad network of national laboratory and industrial partners, together with our advisory council of energy market end–users, positions General Fusion well to help the world achieve its net–zero carbon goals."

General Fusion interacted with, and appreciated the support of, several firms during the Series E financing process, including VAHOCA, based in Singapore, and Disruptive Technology Advisers LLC.

About General Fusion
General Fusion is pursuing the fastest and most practical path to commercial fusion energy and is based in Vancouver, Canada, with locations in London, U.K., and Oak Ridge, Tennessee, U.S.A. The company was established in 2002 and is funded by a global syndicate of leading energy venture capital firms, industry leaders, and technology pioneers. Learn more at www.generalfusion.com.

General Fusion Media Relations
Email: media@generalfusion.com
Phone: 1–866–904–0995

Follow General Fusion

twitter.com/generalfusion

instagram.com/generalfusion

linkedin.com/company/general–fusion

facebook.com/generalfusion

youtube.com/c/GeneralFusionInc


GLOBENEWSWIRE (Distribution ID 8403320)

Todos Medical Enters into Binding Agreement to Acquire All 3CL Protease Biology-Related Assets and Intellectual Property from NLC Pharma

  • Company to form majority owned subsidiary, 3CL Sciences, an entity focused on the development of variant–agnostic COVID–19 antivirals such as Tollovir that utilize the 3CL protease related IP

  • Dr. Dorit Arad, pioneering biology researcher responsible for the discovery of natural 3CL protease inhibitors, to be appointed Chief Scientific Officer of 3CL Sciences

  • Acquisition to include mechanism–based designed new chemical entities targeting 3CL protease and other cellular mechanisms for development of "next–gen' Tollovir candidates

  • Todos Medical to host conference call for the investment community on Thursday, December 2nd, 2021 at 4:30pm ET

NEW YORK and TEL AVIV, Israel, Nov. 30, 2021 (GLOBE NEWSWIRE) — Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced it has entered into a binding agreement to acquire all 3CL protease biology–related assets owned by NLC Pharma and form a majority–owned subsidiary called 3CL Sciences ("3CL Sciences"). 3CL Sciences will be focused on developing therapeutics, diagnostics and dietary supplements based on the pioneering 3CL protease (3CLpro, Main Protease, Mpro, Nsp5) biology work of Dorit Arad, PhD, who will be appointed Chief Scientific Officer of the new company. We believe this acquisition will solidify Todos Medical's position as a key player in the development and commercialization of 3CL protease–related products. These products currently include Tollovir , a therapeutic drug candidate for the treatment of COVID–19 and other nidovirus coronaviruses, TolloTest , a diagnostic testing platform to identify the presence of the 3CL protease related to SARS–CoV–2, and Tollovid & Tollovid Daily, 3CL protease inhibitor dietary supplements that support and maintain healthy immune function. Additionally, the acquisition gives Todos Medical access to discoveries made by Dr. Arad related to the development and commercialization of new chemical entities targeting the 3CL protease and other mechanisms critical for the treatment of COVID–19 using her "mechanism–based design' approach, as well as new designs for mass–scale deployment of the TolloTest technology.

"We began the journey of building 3CL protease biology–based products with Dr. Arad in the second quarter of 2020, just as the pandemic was gaining a foothold globally, and we saw firsthand the power of the technology with initial clinical work on our proprietary diagnostic TolloTest technology," said Gerald E. Commissiong, President & CEO of Todos Medical. "Now more than 18 months after we began collaborating, we have made a number of key discoveries and reached a number of key development and commercial milestones that have only fortified our resolve in bringing products developed from this important biology to the masses. Pfizer's work in the 3CL protease space has undoubtedly created greater interest in our dietary supplement product offerings in the United States and abroad. In Europe we recently announced a dietary supplements distribution license with T–Cell Protect Hellas S.A. (T–Cell Protect) for products based on our Tollovid and Tollovid Daily formulations. Our therapeutic drug candidate, Tollovir, has now advanced to the stage of an interim readout of the Phase 2 clinical data in the treatment of hospitalized COVID–19 patients. Data from our TolloTest demonstrated 100% sensitivity 1–3 days post exposure in a community–based super spreading event setting that, in our view, provided clinical proof of concept for the heightened sensitivity when compared with rapid antigen testing that was the rationale for our initial collaboration. With all these significant scientific advancements resulting from our collaboration with NLC and with the continued proliferation of COVID–19 variants across the globe, we believed now was the perfect time to solidify our relationship with Dr. Arad by officially combining forces through the creation of 3CL Sciences. As a majority owned subsidiary, 3CL Sciences will separate our critical scientific development work in COVID–19 from our other important development–stage work in cancer & Alzheimer's diagnostics, as well as our revenue generating PCR & cPass neutralizing antibody testing services that we offer via our Provista Diagnostics CLIA/CAP lab in the United States. This structure gives us the most flexibility to attract traditional direct private investment into 3CL Sciences from major private institutional investors with the potential to maximize its future value independently to the benefit of Todos shareholders, while limiting ordinary share dilution."

Under the terms of the agreement, Todos Medical will own 60% of 3CL Sciences, and the shareholders of NLC Pharma will own 40% upon the execution of definitive agreements (the "Closing") to acquire all intellectual property and assets related to 3CL protease biology–related products to which NLC Pharma has rights. Todos Medical will assign its European licensing agreement T–Cell Hellas Protect S.A. to 3CL Sciences. Upon the Closing, NLC Pharma Chief Scientific Officer Dr. Dorit Arad and CEO Mr. Avraham Marilus will enter into exclusive executive employment agreements with 3CL Sciences. Todos Medical herein commits to fund 3CL Sciences with initial capital of $2.2 million. In addition NLC Pharma will receive two million dollars ($2,000,000 USD) in cash payments over 15 months, 13,333,000 Ordinary Shares of Todos Medical, and single digit net royalties on 3CL protease–biology related product sales. Todos Medical commits to funding, or assisting 3CL Sciences in obtaining funding, for an aggregate of ten million dollars ($10,000,000 USD) within 6 months of the execution of the Closing. Todos shall also commit its efforts toward facilitating a "Go Public" transaction (IPO, SPAC or reverse merger) for 3CL Sciences within 9 months of the Closing, which may also include a buyout of the unowned 40% of 3CL Sciences in shares by Todos upon mutual agreement. The transaction, which is subject to completion of satisfactory due diligence, is expected to close on December 15th, 2021, or upon another mutually agreed upon date.

"Particularly now with the new Omicron variant causing the SARS–CoV–2 virus to threaten the world again, and potentially decrease the effectiveness of current vaccines, we believe that our technologies will have a major and timely impact on the course of the COVID–19 pandemic," said Dr. Dorit Arad, Chief Scientific Officer at NLC Pharma. "Mechanism based drug, that overcomes most viral mutations, is the timely solution to upcoming new variant threats, and we are excited to take the Tollovir program forward with Todos through the pending Phase 2 interim readout in hospitalized COVID–19 patients and towards registration studies and/or Emergency Use Authorization. We will also now begin to advance discovery–stage next generation small molecule compounds based on Tollovir into pre–clinical development. In parallel, we have now identified what we believe is the best design for a highly scalable deployment of our rapid TolloTest diagnostic platform as the optimal solution for global airports and mass entry points, as well as a viral infectivity monitoring tool for hospitalized COVID–19 patients. As we build up 3CL Sciences based upon the discovery of the fundamental roles of the 3CL protease in SARS–CoV–2 and the development and commercialization of natural 3CL protease inhibitors and diagnostic tests, we believe now diversifying our product portfolio with mechanism–based drug design small molecule 3CL protease inhibitors based on Tollovir will align us with traditional drug development to make 3CL Sciences more attractive for institutional investors and pharmaceutical corporate partners. In conclusion, we are very excited about the future of 3CL Sciences."

Concurrent with this announcement, the Company intends to host a business update conference call for the investment community on Thursday, December 2nd, 2021 at 4:30pm Easter Time. Details to log into the conference call will be made available by the Company on its website, on social media and in a subsequent press release on or before December 1st, 2021.

For more information, please visit www.todosmedical.com. For more information on the Company's CLIA/CAP certified lab Provista Diagnostics, Inc. please visit www.provistadx.com.

About Dr. Dorit Arad
Dr. Dorit Arad is a D.C. in physical organic chemistry from the Technion who has more than 25 years of experience in the life science industry as an international researcher, executive and entrepreneur. Dr. Arad is a pioneer in the discovery and development 3CL protease biology related products and product candidates. Dr. Dorit Arad is an interdisciplinary scientist with expertise in Computer assisted Drug Design, Biotechnology, mechanism–based drug design, Diagnostics, infectious disease and cancer.

About Tollovir
Tollovir is a 3CL protease inhibitor and anti–cytokine therapeutic candidate for the treatment of the nidovirus subcategory of coronaviruses that includes SARS–CoV–2, COVID–19, SARS–CoV–1, MERS and 229E. Tollovir is made from all natural ingredients that are qualified to ensure strong inhibition of the 3CL protease in vitro, as well as strong anti–cytokine activity. Tollovir is currently in a Phase 2 clinical trial in Israel for the treatment of patients hospitalized with COVID–19. Tollovir will be developed for the treatment of hospitalized COVID–19 (severe and critical), moderate COVID–19, long–haul COVID and potentially pediatric COVID–19. Todos has licensed rights for Tollovir to T–Cell Protect Hellas S.A. for the Greek market.

About TolloTest
TolloTest is a 3CL protease diagnostic fluorescence platform technology that has demonstrated clinical proof of concept in hospital setting and outpatient settings in correctly identifying patients infected with COVID–19, including within 1–3 days of first exposure. TolloTest diagnostic tools are being developed to address key deficiencies with current SARS–CoV–2 rapid antigen and PCR technologies. TolloTest can provide results in less than ten (10 minutes), and potentially in as little as two (2) minutes. Data generated from two studies conducted with TolloTest demonstrate that: (1) it can identify SARS–CoV–2 infected patients earlier than rapid antigen testing (potentially earlier than PCR testing), (2) it can identify patients who are likely no longer infectious, but still test positive by PCR and (3) it can identify patients that are still likely infectious, but who have been released from quarantine based on time from positive PCR test. TolloTest assay formats are being developed for (1) point–of–care/at–home market and (2) rapid mass screening in community settings (airports, schools, offices)

About Tollovid & Tollovid Daily
Tollovid and Tollovid Daily are dietary supplement products, made from natural ingredients, that help support and maintain healthy immune function, and are also 3CL protease inhibitor products based upon in vitro functional assays that show inhibition of 3CL protease activity. Tollovid's 3CL protease inhibition activity release criteria is at least twice as stringent as Tollovid Daily's 3CL protease inhibition release criteria. Tollovid has a 5–day dosing regimen, with 4 doses of 3 pills taken each day that provides maximum immune support. Tollovid Daily is a twice daily immune support product that is designed to provide ongoing daily immune support for the person on the go.

About T–Cell Protect Hellas S.A.
T–Cell Protect Hellas (www.tcellprotect.com), based in Athens, Greece, is a European nutraceutical manufacturer and supplier of immune support dietary supplement products that is led by a world–class management team. The company has a retail distribution network of over 11,000 stores throughout Greece. Mr. Filippopoulos, the founder of the company, has been in the natural supplement industry for over 35 years and has launched some of the most well–known products in Europe with his vast retail network relationships. T–Cell Protect is rolling out the Tollovid family of Products under the T–Cell brand throughout Europe.

About Todos Medical Ltd.
Founded in Rehovot, Israel with offices in New York City, Todos Medical Ltd. (OTCQB: TOMDF) engineers life–saving diagnostic solutions for the early detection of a variety of cancers. The Company's state–of–the–art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer–screening technology using peripheral blood analysis that deploys deep examination into cancer's influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. Todos' two internally–developed cancer–screening tests, TMB–1 and TMB–2, have received a CE mark in Europe. Todos recently acquired U.S.–based medical diagnostics company Provista Diagnostics, Inc. to gain rights to its Alpharetta, Georgia–based CLIA/CAP certified lab currently performing PCR COVID testing and Provista's proprietary commercial–stage Videssa breast cancer blood test.

Todos is also developing blood tests for the early detection of neurodegenerative disorders, such as Alzheimer's disease. The Lymphocyte Proliferation Test (LymPro Test) is a diagnostic blood test that determines the ability of peripheral blood lymphocytes (PBLs) and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle. It is believed that certain diseases, most notably Alzheimer's disease, are the result of compromised cellular machinery that leads to aberrant cell cycle re–entry by neurons, which then leads to apoptosis. LymPro is unique in the use of peripheral blood lymphocytes as a surrogate for neuronal cell function, suggesting a common relationship between PBLs and neurons in the brain.

Todos has entered into distribution agreements with companies to distribute certain novel coronavirus (COVID–19) test kits. The agreements cover multiple international suppliers of PCR testing kits and related materials and supplies, as well as antibody testing kits from multiple manufacturers after completing validation of said testing kits and supplies in its partner CLIA/CAP certified laboratory in the United States. Additionally, Todos has entered into a joint venture with NLC Pharma to pursue the development of diagnostic tests targeting the 3CL protease, as well as 3CL protease inhibitors that target a fundamental reproductive mechanism of coronaviruses.

For more information, please visit https://www.todosmedical.com/.

Forward–looking Statements

Certain statements contained in this press release may constitute forward–looking statements. For example, forward–looking statements are used when discussing our expected clinical development programs and clinical trials. These forward–looking statements are based only on current expectations of management, and are subject to significant risks and uncertainties that could cause actual results to differ materially from those described in the forward–looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for product candidates; competition from other biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward–looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; and laboratory results that do not translate to equally good results in real settings, all of which could cause the actual results or performance to differ materially from those contemplated in such forward–looking statements. Except as otherwise required by law, Todos Medical does not undertake any obligation to publicly release any revisions to these forward–looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Todos Medical, please refer to its reports filed from time to time with the U.S. Securities and Exchange Commission.

Todos Corporate and Investor Contact:
Richard Galterio
Todos Medical
732–642–7770
rich.g@todosmedical.com


GLOBENEWSWIRE (Distribution ID 8403084)

Eagle Eye Networks Forecasts Key Video Surveillance Trends for 2022

AUSTIN, Texas, Nov. 30, 2021 (GLOBE NEWSWIRE) — Eagle Eye Networks, the global leader in cloud video surveillance, today released the 2022 edition of its annual Trends in Video Surveillance ebook, a forecast for business leaders and owners who want to understand the physical security landscape and plan for success in 2022.

"Almost two years into the global pandemic, businesses have experienced sustained disruptions in the supply chain, labor shortage challenges, and vast changes in workplace routines," said Dean Drako, Eagle Eye Networks CEO. "Business owners' reliance on video surveillance is increasing because the security and operational insights provided by video surveillance are helping them adapt to the new business environment. Concurrently, the emergence of artificial intelligence (AI) combined with cloud video surveillance promises better, faster, and more accurate analytics for security and business optimization. We expect businesses to rely even more on cloud–based AI analytics to help them thrive in 2022."

To learn what the following five trends mean for your business, and more insights, download the free 2022 Trends in Video Surveillance ebook here.

Video Surveillance Trends for 2022:

  1. Businesses want the flexibility to add customized analytics to their video surveillance systems.
  2. Video surveillance will help businesses impacted by the labor shortage do more with less.
  3. More customers are understanding the business intelligence value of video surveillance.
  4. Pandemic trends around remote work and home and curbside delivery are here to stay.
  5. Interoperability is key to data management and security.

ABOUT EAGLE EYE NETWORKS
Eagle Eye Networks is the global leader in cloud video surveillance, delivering cyber–secure cloud–based video with artificial intelligence (AI) and analytics to make businesses more efficient and the world a safer place. The Eagle Eye Cloud VMS (video management system) is the only platform robust and flexible enough to power the future of video surveillance and intelligence. Eagle Eye is based in Austin, Texas with offices in Amsterdam, Bangalore, and Tokyo. Learn more at een.com.

EAGLE EYE PRESS CONTACT
GLOBAL HQ
Martha Entwistle
mentwistle@een.com
+1–512–473–0500

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a8872386–691a–4de9–8a92–f85f0e23865e


GLOBENEWSWIRE (Distribution ID 8402620)

FXCM October Single Share & Stock Baskets Report

JOHANNESBURG, South Africa, Nov. 29, 2021 (GLOBE NEWSWIRE) — FXCM Group, LLC ("FXCM Group' or "FXCM'), the leading international provider of online foreign exchange trading, CFD trading, cryptocurrencies and related services, is today releasing its data of most popular instruments for the month of October in its Single Share CFD and proprietary Stock Basket product lines.

FXCM offers fractional single share trading with no commission fees* on leading companies from the US, UK, France, Germany, Hong Kong and Australia. FXCM's stock basket products combine the shares of multiple companies from one sector into a single tradeable instrument. The company currently boasts a portfolio of 14 stock baskets. The list of companies and weightings is available on FXCM's stock basket website (https://www.fxcm.com/za/stock–baskets/)

Tesla has been the top single share instrument for three consecutive months, followed by Apple, Amazon, and Facebook, soon to be known by the new symbol MVRS after its rebranding to Meta in late October. PayPal Holdings joined the top 10 club for the first time, slotting in above NVIDIA and Alphabet.

It was also a big month for Biotechnology, which jumped eight places from 10th to be the second highest basket in October, trailing only FAANG in FXCM customer interest. On the other hand, the only HK listed basket ATMX (Big China Tech), the Chinese equivalent of FAANG, fell from No. 2 in September to No. 9 in October as traders' interests were predominantly on the US market.

Volume Rank Monthly Rank Change Company Symbol
1 – Tesla Inc TSLA.us
2 '2 Apple Inc AAPL.us
3 '2 Amazon.com Inc AMZN.us
4 '3 Facebook (Meta Platforms Inc) FB.us
5 "2 Alibaba Group Holding Ltd ADR BABA.us
6 "4 Tencent Holdings Ltd TENC.hk
7 '2 Boeing Company BA.us
8 New to Top 10 PayPal Holdings Inc PYPL.us
9 "3 NVIDIA Corporation NVDA.us
10 '1 Alphabet Inc GOOG.us

Volume Rank Monthly Rank Change Sector Symbol
1 – Big US Tech FAANG
2 '8 Biotechnology BIOTECH
3 '1 China Tech CHN.TECH
4 '1 China Ecommerce CHN.ECOMM
5 '2 US Banks US.BANKS
6 '3 Cannabis CANNABIS
7 "1 Airlines AIRLINES
8 – Travel & Hospitality TRAVEL
9 "7 Big China Tech (HKD Basket) ATMX
10 "5 US E–Commerce US.ECOMM

Past Performance and popularity is not an indicator of future results.
Rank is derived from FXCM Client Volume

*FXCM can be compensated in several ways, which includes but are not limited to adding a mark–up to the spreads it receives from its liquidity providers, adding a mark–up to rollover, etc. Commission–based pricing is applicable to Active Trader account types.

About FXCM:

FXCM is a leading provider of online foreign exchange (FX) trading, CFD trading, and related services. Founded in 1999, the company's mission is to provide global traders with access to the world's largest and most liquid market by offering innovative trading tools, hiring excellent trading educators, meeting strict financial standards and striving for the best online trading experience in the market. Clients have the advantage of mobile trading, one–click order execution and trading from real–time charts. In addition, FXCM offers educational courses on FX trading and provides trading tools, proprietary data and premium resources. FXCM Pro provides retail brokers, small hedge funds and emerging market banks access to wholesale execution and liquidity, while providing high and medium frequency funds access to prime brokerage services via FXCM Prime. FXCM is a Leucadia Company.

Forex Capital Markets Limited: FCA registration number 217689 (www.fxcm.com/uk)

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.

67% of retail investor accounts lose money when trading CFDs with this provider.

You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

FXCM EU LTD: CySEC license number 392/20 (www.fxcm.com/eu)

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.

Between 74–89% of retail investor accounts lose money when trading CFDs.

You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

FXCM Australia Pty. Limited: AFSL 309763.You can sustain a total loss of deposited funds. The products may not be suitable for all investors. Please ensure that you fully understand the risks involved. If you decide to trade products offered by FXCM AU, you must read and understand the Financial Services Guide, Product Disclosure Statement, Target Market Determination and Terms of Business on www.fxcm.com/au.

FXCM South Africa (PTY) Ltd: FSP No 46534 (www.fxcm.com/za). Our service includes products that are traded on margin and carry a risk of losses in excess of your deposited funds. The products may not be suitable for all investors. Please ensure that you fully understand the risks involved.

FXCM Markets Limited: Losses can exceed deposited funds. (www.fxcm.com/markets).

Media contact:
Chatsworth Communications
+44 (0) 20 7440 9780
fxcm@chatsworthcommunications.com


GLOBENEWSWIRE (Distribution ID 8402130)

Adagio Therapeutics Reports That None of the Mutations Present in SARS-CoV-2 Variant, Omicron, Are Associated with Escape from ADG20 Neutralization In Vitro

Additional in vitro studies to determine neutralization activity of ADG20 against Omicron are ongoing

ADG20 EUA submissions planned for prevention and treatment of COVID–19 in mid–2022

Inventory build continues in anticipation of EUA in second half of 2022, with 4 million doses available for distribution over the next two years

WALTHAM, Mass., Nov. 29, 2021 (GLOBE NEWSWIRE) — Adagio Therapeutics, Inc., (Nasdaq: ADGI) a clinical–stage biopharmaceutical company focused on the discovery, development and commercialization of antibody–based solutions for infectious diseases with pandemic potential, today provided information related to the potential of its lead SARS–CoV–2 antibody, ADG20, to address the Omicron SARS–CoV–2 variant, and other known variants of concern. ADG20 is an investigational monoclonal antibody (mAb) product candidate designed to provide broad and potent neutralizing activity against SARS–CoV–2, including variants of concern, for the prevention and treatment of COVID–19 with potential duration of protection for up to one year in a single injection.

"The continued global scale of the COVID–19 pandemic has led to increased levels of immune pressure on the virus, which is driving the emergence of variants containing mutations associated with escape from common classes of neutralizing antibodies induced by natural infection or vaccination. Unlike most antibodies currently available under EUA, ADG20 has been shown to target an epitope that is highly conserved among clade I sarbecoviruses and that is not readily targeted by the endogenous neutralizing antibody response," said Laura Walker, Ph.D., co–founder and chief scientific officer of Adagio. "Due to the highly conserved and immunorecessive nature of the epitope recognized by ADG20, we expect that ADG20 will retain activity against Omicron, as we have observed in in vitro models with all other variants of concern identified previously. Further, none of the mutations present in the spike protein of the Omicron variant have been associated with escape from ADG20 neutralization. ADG20 was engineered for potent and broadly neutralizing activity in anticipation of both the rapid antigenic evolution of SARS–CoV–2 and the emergence of future SARS–like viruses with pandemic potential."

"ADG20 was uniquely designed to combine breadth, potency and duration of protection against SARS–CoV–2 for up to one year in a single injection. We did this anticipating that SARS–CoV–2 would continue to evolve and potentially render some early therapies and vaccines obsolete," said Tillman Gerngross, Ph.D., co–founder and chief executive officer of Adagio. "Our global clinical trials are advancing with potential EUA submissions in mid–2022 for both prevention and treatment of COVID–19. We continue to engage with the FDA and other regulatory bodies and governmental agencies to discuss potential acceleration of development plans and the need for a portfolio of therapeutic solutions to combat the COVID–19 pandemic."

Given the significant potential health crisis resulting from the emergence of Omicron, Adagio is undertaking a number of activities to support ADG20's utility in addressing this newly emerged variant of concern, including:

  • Conducting in vitro studies to evaluate the expected binding and neutralizing activity of ADG20 against Omicron. Initial data from these studies is anticipated by the end of the year; and
  • Recruiting patients in Adagio's Phase 2/3 COVID–19 treatment trial, known as STAMP, across several clinical sites in South Africa (along with ongoing clinical trial efforts globally) in an effort to generate clinical data for ADG20 against infections due to the Omicron variant.

Based on the data being generated, Adagio plans to engage with health authorities and government agencies to accelerate development and supply of ADG20 to combat SARS–CoV–2 and its variants of concern.

ADG20 and Variants of Concern
The neutralizing antibody response induced by SARS–CoV–2 infection and vaccination is dominated by three classes of receptor binding domain (RBD)–directed antibodies (Class 1, Class 2 and Class 3), which often share common escape mutations. The newly emerged Omicron (B.1.1.529) variant identified in South Africa contains mutations associated with resistance to a large proportion of these commonly elicited antibodies, which may be due to immune pressure on these antigenic sites. Data for most antibodies available under EUA or in late–stage clinical development show they target one of these three dominant antigenic regions within the RBD.

In vitro studies have shown that ADG20 binds to a highly conserved epitope within the RBD that is not targeted by any of the common classes of neutralizing antibodies induced by SARS–CoV–2 infection and vaccination. Thus, unlike many other clinical–stage antibodies, which were isolated from COVID–19 patients and recognize epitopes that are also targeted by endogenous neutralizing antibodies, there is limited immune pressure on the ADG20 binding site. The ADG20 epitope has remained conserved in 99.99% of the nearly 4 million full length SARS–CoV–2 viral sequences deposited in the GISAID database as of October 15, 2021, and, as shown in in vitro studies, ADG20 retains activity against prior variants of concern including Alpha, Beta, Delta, and Gamma. For the Omicron variant, none of the mutations present in the spike protein are associated with escape from ADG20 neutralization. Based on published epitope mapping and structural studies, Adagio anticipates that ADG20 will retain neutralizing activity against the Omicron variant whereas other mAb products may lose substantial activity against this variant.

Previously disclosed in vitro data demonstrated retained neutralizing activity of ADG20 against a diverse panel of circulating SARS–CoV–2 variants, including the recently emerged Lambda, Mu and Delta plus variants. Notably, findings from these in vitro studies showed that ADG20 demonstrated potent neutralizing activity against all SARS–CoV–2 variants of concern tested, including those with reduced susceptibility to mAb products currently available under EUA or in late–stage development.

About ADG20
ADG20, an investigational monoclonal antibody targeting the spike protein of SARS–CoV–2 and related coronaviruses, is advancing through global clinical trials for the prevention and treatment of COVID–19, the disease caused by SARS–CoV–2. ADG20 was designed and engineered to possess high potency and broad neutralization activity against SARS–CoV–2 and additional clade 1 sarbecoviruses by targeting a highly conserved epitope in the receptor binding domain. ADG20 was further engineered to provide an extended half–life for durable protection. ADG20 has demonstrated potent neutralizing activity against the original SARS–CoV–2 virus, SARS–CoV–2 variants of concern Alpha, Beta, Delta, and Gamma, other SARS–CoV–2 variants to date, and additional SARS–like viruses in preclinical studies. ADG20 is administered in clinical trials by a single intramuscular injection. To date, ADG20 has been well–tolerated in a Phase 1 trial with no safety signals identified through a minimum of three months follow–up across all cohorts. ADG20 has not been approved for use in any country, and safety and efficacy have not yet been established.

About Adagio Therapeutics
Adagio (Nasdaq: ADGI) is a clinical–stage biopharmaceutical company focused on the discovery, development and commercialization of antibody–based solutions for infectious diseases with pandemic potential, including COVID–19 and influenza. The company's portfolio of antibodies has been optimized using Adimab's industry–leading antibody engineering capabilities and is designed to provide patients and clinicians with the potential for a powerful combination of potency, breadth, durable protection (via half–life extension), manufacturability and affordability. Adagio's portfolio of SARS–CoV–2 antibodies includes multiple non–competing, broadly neutralizing antibodies with distinct binding epitopes, led by ADG20. Adagio has secured manufacturing capacity for the production of ADG20 with third–party contract manufacturers to support the completion of clinical trials and initial commercial launch, ensuring the potential for broad accessibility to people around the world. For more information, please visit www.adagiotx.com.

Forward Looking Statements
This press release contains forward–looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipates," "believes," "expects," "intends," "projects," and "future" or similar expressions are intended to identify forward–looking statements. Forward–looking statements include statements concerning, among other things, the timing, progress and results of our preclinical studies and clinical trials of ADG20, including the timing of our planned EUA submissions, initiation, modification and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs; the expected neutralizing activity of ADG20 against the Omicron variant; our ability to obtain and maintain regulatory approvals for, our product candidates; our ability to identify patients, including in specific populations, with the diseases treated by our product candidates and to enroll these patients in our clinical trials; our expectations regarding the scope of any approved indication for ADG20; and the risk/benefit profile of our product candidates to patients; our manufacturing capabilities and strategy, including plans for doses available in the near future; and our ability to successfully commercialize our product candidates. We may not actually achieve the plans, intentions or expectations disclosed in our forward–looking statements and you should not place undue reliance on our forward–looking statements. These forward–looking statements involve risks and uncertainties that could cause our actual results to differ materially from the results described in or implied by the forward–looking statements, including, without limitation, the impacts of the COVID–19 pandemic on our business, clinical trials and financial position, unexpected safety or efficacy data observed during preclinical studies or clinical trials, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, and the uncertainties and timing of the regulatory approval process. Other factors that may cause our actual results to differ materially from those expressed or implied in the forward–looking statements in this press release are described under the heading "Risk Factors" in Adagio's Quarterly Report on Form 10–Q for the quarter ended June 30, 2021 and in Adagio's future reports to be filed with the SEC, including Adagio's Quarterly Report on Form 10–Q for the quarter ended September 30, 2021. Such risks may be amplified by the impacts of the COVID–19 pandemic. Forward–looking statements contained in this press release are made as of this date, and Adagio undertakes no duty to update such information except as required under applicable law.

Contacts:
Media Contact:
Dan Budwick, 1AB
Dan@1abmedia.com

Investor Contact:
Monique Allaire, THRUST Strategic Communications
monique@thrustsc.com


GLOBENEWSWIRE (Distribution ID 8401774)

ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Höegh LNG Partners LP Investors to Secure Counsel Before Important Deadline in First Filed Securities Class Action Commenced by the Firm – HMLP

NEW YORK, Nov. 27, 2021 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Hegh LNG Partners LP (NYSE: HMLP) between August 22, 2019 and July 27, 2021, inclusive (the "Class Period"), of the important December 27, 2021 lead plaintiff deadline in the securities class action first filed by the firm.

SO WHAT: If you purchased Hegh securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Hegh class action, go to http://www.rosenlegal.com/cases–register–2140.html or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 27, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose: (1) Hegh LNG Partners LP (the "Partnership") was facing issues with the PGN FSRU Lampung charter; (2) as a result, the PGN FSRU Lampung charterer would state that it would commence arbitration to declare the charter null and void, and/or to terminate the charter, and/or seek damages; (3) the Partnership would need to find alternative refinancing for its PGN FSRU Lampung credit facility; (4) the PGN FSRU Lampung credit facility matured in September 2021, not October 2021 as previously stated; (5) the Partnership would be forced to accept less favorable refinancing terms with regards to the PGN FSRU Lampung credit facility; (6) Hegh LNG would not extend the revolving credit line to the Partnership past its maturation date; (7) Hegh LNG would reveal that it "will have very limited capacity to extend any additional advances to the Partnership beyond what is currently drawn under the facility"; (8) as a result of the foregoing, the Partnership would essentially end distributions to common units holders; (9) the COVID–19 pandemic was not the sole or root cause of the Partnership's issues in Indonesia, in 2019, before the pandemic, there were already a very low amount of demand in Indonesia for the Partnership's gas; (10) the auditing, tax, nor maintenance of PGN FSRU Lampung were not the sole or root cause(s) of the Partnership's issues in Indonesia; and (11) as a result, defendants' statements about its business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Hegh class action, go to http://www.rosenlegal.com/cases–register–2140.html or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

———————————————–

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 8400639)

EQUITY ALERT: ROSEN, A LEADING LAW FIRM, Encourages Peloton Interactive, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – PTON

NEW YORK, Nov. 27, 2021 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Peloton Interactive, Inc. (NASDAQ: PTON) between December 9, 2020 and November 4, 2021, inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 18, 2022.

SO WHAT: If you purchased Peloton securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Peloton class action, go to http://www.rosenlegal.com/cases–register–2204.html or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 18, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants repeatedly, falsely assured investors that the Company's positive results and growth would continue after the pandemic. In addition, during the Class Period, Defendants made false and misleading statements about the amount of inventory that Peloton held, and touted the Company's ability to keep its inventory levels in line with substantial, sustained demand. As a result of defendants' misrepresentations, Peloton common stock traded at artificially inflated prices during the Class Period. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Peloton class action, go to http://www.rosenlegal.com/cases–register–2204.html or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

———————————————–

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 8401272)

ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages Silverback Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – SBTX

NEW YORK, Nov. 26, 2021 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Silverback Therapeutics, Inc. (NASDAQ: SBTX): (1) pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company's December 3, 2020 initial public offering ("IPO"); and/or (2) between December 3, 2020 and September 10, 2021, inclusive (the "Class Period"), of the important January 4, 2022 lead plaintiff deadline.

SO WHAT: If you purchased Silverback securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Silverback class action, go to http://www.rosenlegal.com/cases–register–2200.html or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 4, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, the IPO documents featured and defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Silverback's lead product candidate SBT6050 (a TLR8 agonist linker–payload conjugated to a HER2–directed monoclonal antibody that targets tumors, such as breast, gastric, and non–small cell lung cancers) was less effective than the Company had represented to investors; (2) accordingly, the Company had overstated SBT6050's commercial and/or clinical prospects; and (3) as a result, the IPO documents and defendants' public statements throughout the Class Period were materially false and/or misleading and failed to state information required to be stated therein. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Silverback class action, go to http://www.rosenlegal.com/cases–register–2200.html or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

———————————————–

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 8400623)

Information on the total number of voting rights and shares

REGULATED INFORMATION

Information on the total number of voting rights and shares

Mont–Saint–Guibert (Belgium), November 26, 2021, 10:30 pm CET / 4:30 pm ET "" In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the belowinformation following the exercise of subscription rights and the issue of new shares.

  • Share capital: EUR 4,427,369.69
  • Total number of securities carrying voting rights: 25,772,359 (all ordinary shares)
  • Total number of voting rights (= denominator): 25,772,359 (all relating to ordinary shares)
  • Number of rights to subscribe to securities carrying voting rights not yet issued:
    • 105 "2016 ESOP Warrants" issued on November 3, 2016, entitling their holders to subscribe to a total number of 52,500 securities carrying voting rights (all ordinary shares);
    • 100 "2018 ESOP Warrants" issued on December 12, 2018, entitling their holders to subscribe to a total number of 50,000 securities carrying voting rights (all ordinary shares);
    • 490,500 "2020 ESOP Warrants" issued on February 21, 2020, entitling their holders to subscribe to a total number of 490,500 securities carrying voting rights (all ordinary shares); and
    • 1,400,000 "2021 ESOP Warrants" issued on September 8, 2021, entitling their holders to subscribe to a total number of 1,400,000 securities carrying voting rights (all ordinary shares).

*

* *

For further information, please contact:

Nyxoah
Jeremy Feffer, VP IR and Corporate Communications
jeremy.feffer@nyxoah.com
+1 917 749 1494

Gilmartin Group
Vivian Cervantes
IR@nyxoah.com

Attachment


GLOBENEWSWIRE (Distribution ID 1000580599)

One step closer to interoperability: Applying SNOMED CT’s engine to the International Patient Summary

London, United Kingdom, Nov. 25, 2021 (GLOBE NEWSWIRE) — At SNOMED International's recent October Business Meetings held in London, the organization's governance bodies enacted a decision to extend the core of SNOMED CT's structured clinical terminology to deliver an open, standalone sub–ontology to support the scope of content within the International Patient Summary (IPS.)

The IPS is an electronic health record extract containing essential healthcare information for use in the unscheduled, cross–border care scenario, as well as for local, regional and other care scenarios. It is a minimal, non–exhaustive set of data elements defined by ISO/EN 17269 and delivered by HL7 in both CDA and FHIR using a curated set of SNOMED CT terms.

There is a groundswell of support across all health sectors to increase the portability and usability of patient information for the purpose of safe health care delivery. In 2019, SNOMED International and HL7 International announced the formalization of a license agreement in which a relevant "Free for Use' Set of SNOMED CT coded concepts would be used within the HL7 IPS. Most recently, we watched as G7 leaders collaborated to release a communique on the dire need to progress a global health interoperability agenda. IBM offers a working definition of interoperability as "the timely and secure access, integration and use of electronic health data so that it can be used to optimize health outcomes for individuals and populations." The G7 communique, which highlighted the importance of enabling digital healthcare systems worldwide to work together seamlessly as patients move between providers, facilities and even countries, is an impactful statement that rippled throughout the global health community. A charge taken up by the Global Digital Health Partnership, it is one SNOMED International is eager to support.

Embracing a collaborative approach, "SNOMED International has been pleased to continue to work with HL7 International and partners across Europe and beyond to define SNOMED CT content for use in the International Patient Summary," offered SNOMED International Management Board Chair, Joanne Burns.

Continuing to act in the spirit of the IPS Freeset, SNOMED International has committed to create and release an openly available IPS sub–ontology in the first half of 2022 to enhance the existing cross border movement of information, and ultimately health system interoperability. Unlike SNOMED International's Global Patient Set, a flat list of SNOMED CT codes and terms, an IPS sub–ontology will provide implementers with a product that can be used in healthcare solutions using the power of SNOMED CT through its query language and hierarchies for the specified scope. Use of the IPS sub–ontology will allow for more effective use of clinical data analytics and decision support, and for Artificial Intelligence applications.

Alex Elias, Chair of SNOMED International's General Assembly, the organization's Member governance body, has observed a significant increase in discussion regarding the IPS. "2021 has seen increased interest by governments and Health and Care organizations globally for implementing the IPS to enhance timely cross border health information flow and interoperability. This has been a primary driver in SNOMED International supporting this recent initiative to make the IPS sub–ontology openly available with SNOMED CT content."

An organization with an extensive history and active program of collaboration, SNOMED International CEO, Don Sweete, has played a pivotal role in positioning the IPS sub–ontology as a "soon to be achieved' reality. "As the G7 Health Ministers recently indicated, the importance of enabling digital healthcare systems worldwide to work together seamlessly so patients don't suffer as they move between providers, facilities and even countries is a sentiment that has rippled throughout the global health community", offered Sweete. He went on to state that, "continued work with fellow health standards development, national, clinical and technical entities, SNOMED International will dedicate resources to achieve the goal of digital health interoperability." Sweete added, "equipping the IPS, already one of the best examples of international collaboration among standards bodies, with the full capability of SNOMED CT's ontological design is a significant action that we can contribute to achieving health information access gains for patients."

Over the coming months, SNOMED International is formalizing the steps and due diligence required to make the IPS sub–ontology available for broad release. Throughout this period, SNOMED International will continue to define the IPS sub–ontology, from content through to its release and maintenance approach for launch in the first half of 2022.

Visit SNOMED International's IPS Sub–Ontology information page or subscribe to the organization's news service to learn more as this initiative progresses. For additional information, contact info@snomed.org.

About SNOMED International

SNOMED International is a not–for–profit organization that owns and develops SNOMED CT, the world's most comprehensive healthcare terminology product. We play an essential role in improving the health of humankind by determining standards for a codified language that represents groups of clinical terms. This enables healthcare information to be exchanged globally for the benefit of patients and other stakeholders. We are committed to the rigorous evolution of our products and services, to deliver continuous innovation for the global healthcare community. SNOMED International is the trading name of the International Health Terminology Standards Development Organisation.

www.snomed.org

Attachment


GLOBENEWSWIRE (Distribution ID 8400494)